# A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer

> **NCT02005315** · PHASE1 · COMPLETED · sponsor: **OncoMed Pharmaceuticals, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** Vantictumab
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02005315
- **Lead sponsor:** OncoMed Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2017-10
- **Final completion:** 2017-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02005315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02005315, "A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02005315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*